Fatty acid-binding protein 5 (FABP5)-related signal transduction pathway in castration-resistant prostate cancer
Abdulghani A Naeem1, Saud A Abdulsamad1, Philip S Rudland2
1The Molecular Pathology Laboratory, Department of Molecular and Clinical Cancer Medicine.
Abstract:
In this short communication, a novel fatty acid-binding protein 5 (FABP5)-related signal transduction pathway in prostate cancer is reviewed. In castration-resistant prostate cancer (CRPC) cells, the FABP5-related signal transduction pathway plays an important role during transformation of the cancer cells from androgen-dependent state to androgen-independent state. The detailed route of this signal transduction pathway can be described as follows: when FABP5 expression is increased as the increasing malignancy, excessive amounts of fatty acids from intra- and extra-cellular sources are transported into the nucleus of the cancer cells where they act as signalling molecules to stimulate their nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ). The phosphorylated or biologically activated PPARγ then modulates the expression of its downstream target regulatory genes to trigger a series of molecular events that eventually lead to enhanced tumour expansion and aggressiveness caused by an overgrowth of the cancer cells with a reduced apoptosis and an increased angiogenesis. Suppressing the FABP5-related pathway via RNA interference against FABP5 has produced a 63-fold reduction in the average size of the tumours developed from CRPC cells in nude mice, a seven-fold reduction of tumour incidence, and a 100% reduction of metastasis rate. Experimental treatments of CRPC with novel FABP5 inhibitors have successfully inhibited the malignant progression of CRPC cells both in vitro and in nude mouse. These studies suggest that FABP5-related signal transduction pathway is a novel target for therapeutic intervention of CRPC cells.
Insights
Fatty acid-binding protein 5 (FABP5) drives castration-resistant prostate cancer (CRPC) progression by activating PPARγ. Inhibiting FABP5 significantly reduces tumor growth, incidence, and metastasis, offering a novel therapeutic target for CRPC.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Castration-resistant prostate cancer (CRPC) cells transition from androgen-dependent to independent states.
- Fatty acid-binding protein 5 (FABP5) expression increases with malignancy in CRPC.
- FABP5 plays a crucial role in CRPC cell transformation and progression.
Purpose of the Study:
- To review the novel FABP5-related signal transduction pathway in prostate cancer.
- To elucidate the role of FABP5 in CRPC progression.
- To identify FABP5 as a potential therapeutic target for CRPC.
Main Methods:
- Review of the FABP5-related signal transduction pathway.
- RNA interference (RNAi) targeting FABP5 in CRPC cells.
- In vitro and in vivo studies using FABP5 inhibitors on CRPC cells in nude mice.
Main Results:
- FABP5 transports fatty acids into the nucleus, stimulating PPARγ activation.
- Activated PPARγ upregulates genes promoting tumor expansion, reduced apoptosis, and increased angiogenesis.
- FABP5 suppression via RNAi led to a 63-fold decrease in tumor size, 7-fold reduction in incidence, and 100% reduction in metastasis.
- FABP5 inhibitors effectively suppressed CRPC progression in vitro and in vivo.
Conclusions:
- The FABP5-related signal transduction pathway is critical for CRPC aggressiveness.
- Targeting FABP5 offers a promising therapeutic strategy for CRPC.
- FABP5 inhibition demonstrates significant anti-cancer effects in preclinical models.
More Related Videos
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Amplifying Signals via Enzymatic Cascade
PI3K/mTOR/AKT Signaling Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against...
Non-Canonical Wnt Signaling Pathways


